focus -WSS

focus

author：explore 2025-10-01 14:19:53 - browse：522

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： AdventHealth escalates lawsuit against insurance vendor Multiplan

WSS

Morgan Health, with ambitious aims, wants you to know it’s still here

Adopting new red light myopia treatments may be short

Videos point to link between seizures and unexplained toddler deaths

340B reform proposal comes out of Senate working group

Feng Zhang CRISPR delivery startup lays off quarter of staff

Global cancer cases to surge 77% by 2050, WHO report says

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Jerome Adams on the need for new antivirals for Covid

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

New air purifier tech could be key to improving indoor air quality

Readout LOUD: Venture capital, Gilead, and more M&A

Moonlake's readout produced a cash windfall. Risks remain

Readout LOUD: Venture capital, Gilead, and more M&A

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Adopting new red light myopia treatments may be short

Alkermes shareholders re

Texas Medical Board asked to define abortion emergency exception

Wikipedia

Burning questions for the 2024 JPM Healthcare Conference

Updated Covid vaccine has 54% effectiveness, new study suggests

Feng Zhang, Grail founder join forces on new gene editing startup

340B reform proposal comes out of Senate working group

Gene therapy for Afghan refugees’ infant will be fully covered

Why psychiatrists like me stop taking insurance

hotspot

explore

focus

hotspot